RxDoctor Payments Data

Laura Leahy

Psychiatric/Mental Health · Sewell, NJNPI 1548352875

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (54.6%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 15 manufacturers reported payments, led by Otsuka America Pharmaceutical, Inc. at 56.3% of the total. Reporting peaked in 2024 at $17,332 and has fallen 58.1% since, to $7,268 in 2025. Among psychiatric/mental health clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$41,184in general payments, 2019–2025

Across 161 payments — averaging $255.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$23K
  • Biogen$6K
  • Janssen Scientific Affairs, LLC$5K
  • Emergent Biosolutions Inc.$5K
  • Bausch Health US, LLC$564
  • Neurocrine Biosciences, Inc.$450
  • plus $399 from 9 others

What the payments were for

  • Consulting fees$11,73728%
  • Speaking & faculty fees$22,48655%
  • Travel & lodging$4,56911%
  • Food & beverage$2,3926%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$41,184 in reported general payments places this provider in the 95th percentile of 1,212 psychiatric/mental health providers in New Jersey.

See all psychiatric/mental health providers in New Jersey

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate26$218,346
TrintellixVortioxetine Hydrobromide40$43,870
Lurasidone Hcl13$8,604
Lisdexamfetamine Dimesylate17$2,827
Bupropion XlBupropion Hcl64$1,434
Autoshield Duo Pen NeedlePen Needle,dual Safety,diabetc13$1,294
Alprazolam68$682
Gabapentin44$636
Duloxetine Hcl24$625
Quetiapine Fumarate24$438
Aripiprazole11$433
Hydroxyzine Hcl17$418
Clonazepam49$395
Lamotrigine15$289
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine13$260

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$450$218,34626 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,212 psychiatric/mental health providers in New Jersey.

Other psychiatric/mental health in Sewell

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →